期刊文献+

艾滋病HAART治疗中免疫重建炎性综合征临床特征与潜在影响因素探讨 被引量:4

Study on clinical features of HAART associated immune reconstitution inflammatory syndrome and its potential risk factors
下载PDF
导出
摘要 目的观察艾滋病患者高效抗逆转录病毒治疗(HAART)启动后发生免疫重建炎性综合(IRIS)的临床特征,并探讨IRIS发生影响因素。方法以2003年6月—2013年6月接受HAART治疗的艾滋病患者102例为研究对象,设立6个月随访期。分别与HAART启动时,启动后90 d和180 d检测患者HIV RNA病毒载量和CD4+细胞计数,根据观察期内是否出现IRIS将患者分为IRIS组(19例)和非IRIS组(83例)。收集2组一般资料,实验室和影像检查资料。结果 IRIS发病率18.6%(19/102),HAART启动后IRIS发生平均为33 d,感染类型以结核分枝杆菌感染为主(57.9%,11/19)。IRIS组和非IRIS组CD4+细胞计数基线比较差异有统计学意义(P〈0.01);HAART启动后2组HIV RNA病毒载量呈下降趋势,CD4+细胞计数呈上升趋势。经分析,HAART启动时CD4+细胞计数(OR=6.45,95%CI∶4.59~15.6)和HAART启动后HIV RNA病毒载量变化(〉2 log10拷贝/m L)(OR=3.12,95%CI∶1.45~6.24)与IRIS发生相关。结论 IRIS多发生于HAART启动后3个月内,HAART启动前基线CD4+细胞水平越低,HAART启动后HIV RNA病毒载量变化越大,则患者IRIS发生风险越大,应积极开展对症抗感染治疗。 Objective To observe clinical features of highly active anti- retroviral therapy( HAART) associated immune reconstitution inflammatory syndrome( IRIS) and explore its potential risk factors. Methods A total of 102 HIV / AIDS patients treated with HAART from June 2003 to June 2013 were selected and followed up for 6 months. Blood sample were collected before HAART,90 days and 180 days after HAART in order to detect level of HIV RNA viral load and CD4+cell count. Patients were assigned to IRIS group( n = 19) and non- IRIS group( n = 83) according to the occurrence of IRIS. Results The incidence of IRIS was 18. 6%( 19 /102),and the average length from initiation to IRIS occurrence was 33 days,and mycobacterium tuberculosis infection was the main infection type( 57. 9%,11 /19). There was significant difference in CD4+cell count at baseline between the IRIS group and the non- IRIS group( P〈0. 01). After HAART initiation,the HIV RNA viral load declined and CD4+cell count increased in both groups. A correlation was found between IRIS occurrence, the CD4+cell count at baseline( OR = 6. 45, 95% CI ∶4. 59 ~ 15. 6) and changes( 〉2 log10 copies / m L) of HIV RNA viral load( OR = 3. 12,95 % CI ∶ 1. 45~ 6. 24). Conclusion IRIS usually occur within 3 months after HAART initiation. The lower level of CD4+cell count at baseline,the greater change of HIV RNA viral load after HARRT initiation,and this correlation may indicate the higher risk of IRIS.
出处 《实用临床医药杂志》 CAS 2015年第7期21-24,共4页 Journal of Clinical Medicine in Practice
基金 全国全球基金艾滋病项目2012年支持社会组织参与艾滋病防治工作项目(CSO-2012-活-15)
关键词 艾滋病病毒 抗逆转病毒治疗 免疫重建炎性综合 结核杆菌 human immunodeficiency virus highly active anti-retroviral therapy immune reconstitution inflammatory syndrome mycobacterium tuberculosis
  • 相关文献

参考文献17

  • 1Cohen M S,Chen Y Q,Mc Cauley M,et al.Prevention of HIV-1 infection with early antiretroviral therapy[J].N Engl J Med,2011,365(6):493.
  • 2Granich R,Gupta S,B Suthar A,et al.Antiretroviral therapy in prevention of HIV and TB:update on current research efforts[J].Curr HIV Res,2011,9(6):446.
  • 3Beatty G W.Immune reconstitution inflammatory syndrome[J].Emerg Med Clin North Am,2010,28(2):393.
  • 4陈武,刘薇芝,胡汉昆,桂希恩.免疫重建炎性综合征研究进展[J].中国全科医学,2011,14(33):3776-3778. 被引量:8
  • 5Haddow L J,Colebunders R,Meintjes G,et al.International Network for the Study of HIV-associated IRIS(INSHI)Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals:proposed clinical case definitions[J].Lancet Infect Dis,2010,10(11):791.
  • 6Muller M,Wandel S,Colebunders R,et al.Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection:a systematic review and meta-analysis[J].Lancet Infect Dis,2010,10(4):251.
  • 7Barber D L,Andrade B B,Sereti I,et al.Immune reconstitution inflammatory syndrome:the trouble with immunity when you had none[J].Nat Rev Microbiol,2012,10(2):150.
  • 8Mahnke Y D,Greenwald J H,Der Simonian R,et al.Selective expansion of polyfunctional pathogen-specific CD4+T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome[J].Blood,2012,119(13):3105.
  • 99 Wilson E M P,Sereti I.Immune restoration after antiretroviral therapy:the pitfalls of hasty or incomplete repairs[J].Immunological Reviews,2013,254(1):343.
  • 1010 Ratnam I,Chiu C,Kandala N B,et al.Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort[J].Clin Infect Dis,2006,42(3):418.

二级参考文献69

  • 1ZHOUHua-ying ZHENGYu-huang ZHANGChun-ying DINGPei-pei ZOUWen.A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy[J].Chinese Medical Journal,2005(7):609-611. 被引量:16
  • 2张子宁,尚红,姜拥军,王亚男,韩晓旭,张民,刘静,刁莹莹,代娣,耿文清.高效抗逆转录病毒治疗对中国HIV/AIDS患者淋巴细胞活化及第二受体表达的影响[J].中华微生物学和免疫学杂志,2005,25(4):343-346. 被引量:4
  • 3郑煜煌,陈军,雷建华,赖力英,朱映华,何艳,罗虹雨,周华英,丁佩佩,张春迎,李慧.高效抗逆转录病毒疗法治疗HIV—1感染者的免疫学变化[J].中华皮肤科杂志,2006,39(5):281-284. 被引量:22
  • 4Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefi- ciency virus infection. HIV Outpatient Study Investigators [ J ]. N Engl J Med, 1998, 338 (13) : 853 -860,.
  • 5Zhang F, Haberer JE, Warty Y, et al. The Chinese free antiretroviral treatment program: challenges and responses [J]. AIDS, 2007, 21 (Suppl 8) : S143 -S148.
  • 6DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in H1V - l - infected persons after initiation of highly active antiret- roviral therapy [ J]. Ann Intern Med, 2000, 133 : 447 -454.
  • 7Robertson J, Meier M, Wall J, et al. Im- mune reconstitution syndrome in HIV: valida- ting a ease definition and identifying clinical predietom in persons initiating antiretmviral therapy [J]. J Clin Infect Dis, 2006, 42: 1639 - 1646.
  • 8Miller RF, lsaaeson PG, Hall- Craggs M. Cerebral CDs lymphocytosis in HI - 1 in- fected patients with immune restoration in- duced by HAART [ J]. Acta Neuropathol, 2004, 108: 17-23.
  • 9Murdoch DM, Ventcr A. Immune reconstitution drome ( IRIS ) : review tious manifestations and WDF, Van Rie inflammatory syn- of common infec- treatment options[J ]. AIDS Research and Therapy, 2007, 4:9.
  • 10Burman W, Weis S, Vernon A, et al. Fre- quency, severity and duration of immune re- constitution events in H1V - related tuberculosis [J ]. Int J Tuberc Lung Dis, 2007, 11: 1282 - 1289.

共引文献17

同被引文献21

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部